Polyethylene Glycols (PEGs) for Pharmaceutical Application
Download PDF
CD Bioparticles is a high-tech company integrating professional R&D, production, and sales, providing customized solutions for the development and production of drug delivery systems (DDS) and new medical materials.
CD Bioparticles has strong technical strength and a high-level research team to develop and produce high-quality polyethylene glycol (PEG) derivatives, which are FDA-approved polymers for use in biomedical products. PEGylation is a chemical modification process that connects PEGylated active derivatives to therapeutic protein/peptide drugs or drug delivery systems. It is an advanced pharmaceutical molecular modification and drug delivery technology in the world. Our facility is ISO9001 and ISO13485 certified, and is operating according to ICH Q7A guidelines to produce PEG derivatives for pharmaceutical companies.
Today we offer you:
A fully certified high purity polydisperse and monodisperse PEG derivatives. These PEG derivatives have been widely used in bioconjugation, antibody-drug conjugates (ADCs) therapeutic, drug delivery, medical materials, diagnostics field, etc.
- High purity pharmaceutical PEG derivatives with an extensive variety of functional groups
- Providing custom PEG derivatives in milligram to hundreds of kilograms or greater with GMP standard manufacturing capability
- Custom analytical test methods for customized PEG derivatives in order to adjust our testing to best fit your needs
- Instant expert scientific support
Polydisperse PEG Derivatives
PEG can be divided into monodisperse PEG and polydisperse PEG. Monodispersed PEG are homogeneous polymers and have a single molecular weight, while Polydisperse PEG are heterogeneous and contain polymer chains of unequal length. Thus the polydisperse PEG molecular weight is not a single value—the polymer exists as a distribution of chain lengths and molecular weights.
Polydisperse PEGs are very useful in the development of PEGylated protein drugs, helping to increase drug half-life and lower clearance rates. For example, poly PEG in PEGylated lipid nanoparticles has been used in COVID-19 mRNA vaccines and gained international attention. PEG lipids have been widely applied to improve the circulation time of liposome-encapsulated (LNP) drugs and reduce nonspecific uptake.
Features
- Diverse product structure
- Rich in substitution
- High substitution rate of end group
Polydisperse PEG Derivatives
| Product Name |
Molecular Weight |
CAS No. |
Structural Formula |
| mPEG-NH2 |
2KDa, 5KDa, 10KDa, 20KDa |
80506-64-5 |
|
|
mPEG-pALD |
2KDa, 5KDa, 10KDa, 20KDa |
125061-88-3 |
|
|
AA-PEG-AA |
2KDa, 5KDa, 10KDa, 20KDa |
26570-48-9 |
|
|
HOOC-PEG-OH |
5KDa, 10KDa, 20KDa, 40KDa |
39927-08-7 |
|
|
2-arm PEG-CHO |
2KDa, 5KDa, 10KDa, 20KDa, 40KDa |
-- |
|
| 4-arm PEG-MAL |
2KDa, 5KDa, 10KDa, 20KDa, 40KDa |
357277-62-4 |
|
| 4-arm PEG-SC |
2KDa, 5KDa, 10KDa, 20KDa, 40KDa |
-- |
|
|
8-arm PEG-NH2 |
5KDa, 10KDa, 20KDa, 40KDa |
-- |
|
Monodisperse PEG Derivatives
Monodisperse PEG products are typically organic compounds with molecular weights less than 1000. The monodisperse of PEGs may play a role in the development of safe and effective PEGylated small-molecule drugs, which can confer flexibility, anticoagulation, anti-macrophage phagocytosis, etc. to the modified biomolecules. Currently, monodisperse PEGs are used in many fields, including nanotechnology, drug release, pharmaceutical industry, and biomedical research.
In drug delivery, PEG can be used as a linker for antibody-drug conjugates (ADCs) or as a surface coating on nanoparticles to improve systemic drug delivery. Previous studies have found that the incorporation of monodisperse PEG into small molecule drugs can increase the solubility and molecular weight of the drug, thereby prolonging the half-life of the drug in vivo, while reducing the steric hindrance and binding effects generated when the protein is modified by high- molecular PEG.
| Product Name |
Structural Formula |
CAS No. |
Structural Formula |
| HO-PEG1-CH2CH2COOtBu |
C9H18O4 |
671802-00-9 |
|
| H2N-PEG2-CH2CH2COOtBu |
C11H23NO4 |
756525-95-8 |
|
| N3-PEG3-OH2CH2COONHS Ester |
CH20N4O7 |
1245718-89-1 |
|
| N3-PEG4-OH |
C8H17N3O4 |
86770-67-4 |
|
| N3-PEG6-CH2COOH |
C14H27O8N3 |
880129-82-8 |
|
| N3-PEG10-CH2CH2NH2 |
C22H46O10N4 |
912849-73-1 |
|
Monodisperse PEG Derivatives
| Product Name |
Structural Formula |
CAS No. |
Structural Formula |
| Fmoc-NH-PEG5-CH2CH2 |
C28H37NO9 |
882847-32-7 |
|
| Boc-NH-PEG3-CH2CH2COOH |
C14H27NO7 |
1347750-75-7 |
|
| N3-PEG6-CH2CO2-NHS |
C18H30N4O14 |
-- |
|
